En DE FR ES PL
Natsef - instructions for use, analogs, reviews and release forms (powder for the preparation of solution for injections and intravenous injection of 0.5 g and 1 g) of the drug for the treatment of bronchitis, cystitis and sinusitis in adults, children and pregnancy. Composition

Natsef - instructions for use, analogs, reviews and release forms (powder for the preparation of solution for injections and intravenous injection of 0.5 g and 1 g) of the drug for the treatment of bronchitis, cystitis and sinusitis in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Nacef. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Nacef in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of the Nacef in the presence of existing structural analogs.Use for the treatment of bronchitis, cystitis, endocarditis, sinusitis or sinusitis in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Nacef - first-generation cephalosporin antibiotic for parenteral use. It acts bactericidal, disrupting the synthesis of the cell wall of microorganisms. Has a wide spectrum of action, is active against Gram-positive (Staphylococcus spp., Staphylococcus aureus (not producing and producing penicillinase, including Streptococcus pneumoniae (streptococcus)), Corynebacterium diphtheriae, Bacillus anthracis) and Gram-negative (Neisseria meningitidis, Neisseria gonorrhoeae, Shigella spp. (Shigella), Salmonella spp. (Salmonella), Escherichia coli (E. coli), Klebsiella spp. (Klebsiella), Treponema spp., Leptospira spp.). It is active against Haemophilus influenzae, some strains of Enterobacter and Enterococcus.

 

Ineffective against Pseudomonas aeruginosa, indolpositive strains of Proteus spp. (Proteus), Mycobacterium tuberculosis (Mycobacteria), Serratia spp., Anaerobic microorganisms, methicillin-resistant strains of Staphylococcus spp.

 

Composition

 

Cefazolin (in the form of sodium salt) + water for injection + auxiliary substances (Naftse with solvent).

 

Cefazolin (in the form of the sodium salt) + auxiliary substances (nateg. Without solvent).

 

Pharmacokinetics

 

Penetrates into joints, tissues of the cardiovascular system, into the abdominal cavity, kidneys and urinary tract, placenta, middle ear, respiratory tract, skin and soft tissues.In small quantities, Nacef is excreted in breast milk. Concentration in the tissue of the gallbladder and bile is much higher than in the serum. With obstruction of the gallbladder, the concentration in the bile is less than in the plasma. Relationship with plasma proteins 85%. The nassef is excreted mainly with the kidneys in unchanged form: within the first 6 hours - 60-90%, after 24 hours - 70-95%.

 

Indications

  • acute and chronic nasopharyngitis (inflammation of the nasopharynx);
  • acute and chronic sinusitis (inflammation of the paranasal sinuses);
  • acute and chronic pharyngitis (inflammation of the mucous throat);
  • chronic rhinitis (inflammation of the nasal mucosa);
  • acute and chronic tonsillitis (inflammation of the tonsils);
  • acute and chronic laryngitis and laryngotracheitis (inflammation of the larynx and trachea);
  • acute and chronic, unspecified bronchitis (inflammation of the bronchi);
  • bacterial pneumonia (pneumonia);
  • urethritis (inflammation of the urethra);
  • cystitis (inflammation of the bladder);
  • acute and chronic pyelonephritis (inflammation of the renal pelvis);
  • Cholangitis (inflammation of the bile ducts);
  • acute and chronic cholecystitis (inflammation of the gallbladder);
  • infections of the genitourinary system (including syphilis and gonorrhea);
  • inflammatory diseases of the prostate;
  • inflammatory diseases of the breast;
  • abscess of the skin (abscess);
  • furuncles and carbuncles (inflammation of the hair follicle);
  • phlegmon (diffuse purulent inflammation of cellulose);
  • pyoderma (purulent skin damage caused by cocci);
  • impetigo (a kind of pyoderma);
  • post-traumatic wound infection;
  • pyogenic arthritis (purulent inflammation of the joints);
  • osteomyelitis (inflammation of bone tissue);
  • acute and subacute endocarditis (inflammation of the endocardium of the heart);
  • streptococcal septicemia (ingestion of bacteria into the blood);
  • acute peritonitis (inflammation of the peritoneum);
  • otitis media (inflammation of the middle ear);
  • inflammation and occlusion of the auditory tube, mastoiditis;
  • prevention of surgical infections in the pre- and postoperative period;
  • Other infectious diseases caused by microorganisms sensitive to cefazolin.

 

Forms of release

 

Powder for the preparation of a solution for intravenous injection and intramuscular injections of 0.5 g and 1 g in a vial.
 
Powder for the preparation of a solution for intravenous administration and intramuscular injections of 0.5 g and 1 g in a vial complete with a solvent (water for injection) in ampoules.

 

Instructions for use and dosing regimen

 

Intramuscularly, intravenously (struyno and drip).

 

The average daily intake for adults is 1 g; the frequency of administration is 2 times a day. The maximum daily dose is 6 g (in rare cases - 12 g); the frequency of administration can be increased up to 3-4 times a day.

 

The average duration of treatment is 7-10 days.

 

For the prevention of postoperative infection 1 g - 30 minutes before surgery, 0.5-1 g - during surgery and 0.5-1 g every 6-8 hours during the day after surgery.

 

Patients with impaired renal function require a change in the dosing regimen in accordance with the values ​​of creatinine clearance (CK). With CC 55 ml per minute or more, or with a plasma creatinine content of 1.5 mg% or less, a full dose can be administered. With SC 54-35 ml per minute, or with a creatinine content of 3-1.6 mg% in plasma - a full dose can be given, but the intervals between injections can be increased to 8 hours. With SC 34-11 ml per minute or creatinine in the plasma 4.5-3.1 mg% - half the dose at intervals of 12 hours. Patients with CC 10 ml per minute or less, or with a plasma creatinine content of 4.6 mg% or more - half the average dose every 18-24 hours. All recommended doses are given after the initial shock dose.

 

The average daily dose for children is 20-50 mg per kg; In severe infection, the dose can be increased to 100 mg per kg per day. Multiplicity of administration -3-4 times a day. In children with impaired renal function, the dosage regimen is adjusted depending on the values ​​of the CC. At CC 70-40 ml per minute - 60% of the average daily dose and injected after 12 hours. With KK 40-20 ml per minute - 25% of the average daily dose with an interval of 12 hours. Children with KK 5-20 ml per minute - one tenth of the average daily dose every 24 hours. All recommended doses are given after the initial shock dose.

 

Preparation of solutions

 

For intramuscular injection, the drug is dissolved in 4-5 ml of water for injection, isotonic sodium chloride solution or 0.25-0.5% solution of novocaine.

 

For intravenous drip, the drug is dissolved in 100-250 ml of isotonic sodium chloride solution or 5% glucose solution; the injection is carried out for 20-30 minutes (rate of administration of 60-80 drops per minute).

 

For intravenous fluid administration, a single dose of the drug is diluted in 10 ml of isotonic sodium chloride solution and injected slowly for 3-5 minutes.

 

During the dilution, the vials are vigorously shaken until completely dissolved.

 

Side effect

  • hyperthermia (fever);
  • rashes, itching;
  • bronchospasm (narrowing of the bronchi);
  • eosinophilia (increase in the number of eosinophils in the blood);
  • urticaria (an allergic rash);
  • Quincke's edema (allergic edema of the larynx);
  • arthralgia (joint pain);
  • anaphylactic shock (allergic reaction of immediate type);
  • erythema multiforme (allergic skin disease);
  • malignant exudative erythema (Stevens-Johnson syndrome);
  • nausea, vomiting;
  • diarrhea;
  • abdominal pain;
  • pseudomembranous enterocolitis (inflammation of the small and large intestine);
  • Cholestatic jaundice (violation of the outflow of bile);
  • hepatitis (inflammation of the liver);
  • convulsions;
  • impaired renal function (in patients with kidney disease when treated with large doses of Nacef);
  • leukopenia (decrease in the number of leukocytes);
  • neutropenia (decrease in the number of neutrophils);
  • thrombocytosis (increase in the number of platelets);
  • thrombocytopenia (decrease in the number of thrombocytes);
  • hemolytic anemia (decrease in the number of erythrocytes due to their destruction);
  • a positive Coombs reaction;
  • increased activity of hepatic transaminases (ALT and AST);
  • hypercreatininaemia (increase of creatinine in blood plasma);
  • increased prothrombin time;
  • dysbacteriosis (changes in the composition of microorganisms that colonize the intestine);
  • superinfection caused by resistant strains;
  • candidamycosis (thrush);
  • candidiasis stomatitis (inflammation of the oral mucosa);
  • pain in the place of intramuscular injection;
  • phlebitis (inflammation of the vein).

 

Contraindications

  • increased sensitivity to cephalosporin group preparations and other beta-lactam antibiotics;
  • pregnancy and lactation, if necessary, breast-feeding is discontinued;
  • Do not appoint a newborn (up to 1 month).

 

Carefully:

  • renal or hepatic insufficiency;
  • pseudomembranous enterocolitis.

 

Application in pregnancy and lactation

 

Natsef is contraindicated during pregnancy and lactation.

 

Use in children

 

Safety of the use of naceph in preterm infants and children of the first year of life is not established.

 

special instructions

 

Patients who had a history of allergic reactions to penicillins, carbapenems may have increased sensitivity to cephalosporin antibiotics.

 

During treatment with cefazolin, positive direct and indirect Coombs probes can be obtained,as well as a false positive urine reaction to sugar.

 

When prescribing the drug, the exacerbation of GIT diseases, especially colitis, is possible.

 

Drug Interactions

 

It is not recommended simultaneous reception with anticoagulants and diuretics. With the simultaneous use of Cefazolin and "loop diuretics", a blockade of its tubular secretion occurs.

 

Aminoglycosides increase the risk of kidney damage. Pharmaceutically incompatible with aminoglycosides (mutual inactivation).

 

Drugs that block tubular secretion, increase concentration in the blood, slow down excretion and increase the risk of developing toxic reactions.

 

Analogues of the drug Nacef

 

Structural analogs for the active substance:

  • Anceph;
  • Zolin;
  • Intrazoline;
  • Iphizol;
  • Kefzol;
  • Lysolin;
  • Orpin;
  • Totatsef;
  • Cesolin;
  • Cefazolin;
  • Cefamezin;
  • Cefaprim;
  • Cephezole;
  • Cefopride.

 

Doctor's Feedbackotorhinolaryngologist

 

Like the other first-generation cephalosporins, Nacef is affordable and has a fairly broad spectrum of action: it works against most gram-positive and many gram-negative pathogens.A significant drawback is a weak ability to penetrate the blood-brain barrier, so this antibiotic is ineffective in meningitis. Another minus in exclusively parenteral administration, the absence of forms for oral administration. Therefore, with moderate and mild disease, I usually prescribe cephalosporins of the second and third generation (Zinnat, Cefixim) in tablets. But for the treatment of severe bronchitis and pneumonia in a hospital, Nacef can serve as a drug of choice. Before the first introduction of an antibiotic, it is necessary to carry out a sample for sensitivity, since allergic reactions are not uncommon.

Similar medicines:

Other medicines:

Reviews (0):

Rules for publishing reviews and visitor questions